Post-transplant maintenance with revumenib in children with HOX-driven AML
Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), Georgina El Hajjar(The University of Texas MD Anderson Cancer Center), Sofía Garcés(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), Olayinka Okeleji(The University of Texas MD Anderson Cancer Center), César Núnêz(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Samanta Catueno(The University of Texas MD Anderson Cancer Center), Aziz Farhat(The University of Texas MD Anderson Cancer Center), Alexandra M. Stevens(Baylor College of Medicine)
Cited by 2
Related Papers
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
|Journal of Clinical Oncology|2021|333